When this page refreshes you will be logged in with the new address. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Image source: The Motley Fool. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. Watch list NEW Set a price target alert After Hours Last. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. By continuing to use our service, you agree to our use of cookies. 35 as of 10:41 a. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. One reason for that is that this tier does not include penny stocks. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. THTX | Complete Theratechnologies Inc. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. 49) by $0. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 9 million, adjusted EBITDA of $2. Theratechnologies Inc. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. Read More. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. This module allows you to check different measures of market premium (i. 0. Stockhouse. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. com uses cookies on this site. com. 06 million, an increase of 14. Stockhouse. 22, 2023 /CNW/ - Northwest Healthcare Properties Real Estate Investment Trust (the "REIT" or "Northwest") (TSX: NWH. Learn why it. home message. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. 9%, while the Biotechs industry saw earnings growing at 17. MONTREAL, Oct. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. com uses cookies on this site. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. A live webcast of Dr. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. R. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. By continuing to use our service, you agree to our use of cookies. T. The Theratechnologies Inc. 00. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. We also use them to share usage information with our partners. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. GUD | Complete Knight Therapeutics Inc. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Theratechnologies Stock Price, News and Company Updates. Vice President, Communications and Corporate Affairs. 29(+0. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. We also use them to share usage. (“Theratechnologies”) with the Securities and Exchange Commission (the. Stockhouse. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. 4 million. 57%) Q1 2020 Earnings Call. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Theratechnologies Inc. - Cash, bonds and money market funds of US$22. We also use them to share. Focused on small-cap companies and sectors. Stockhouse. By continuing to use our. Competitors: Unknown. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. org. GlobeNewswire. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Apr 14, 2020, 8:30 a. By continuing to use our service, you agree to our use of cookies. Stockhouse. European Headquarters. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. By continuing to use our service, you agree to our use of cookies. View real-time stock prices and stock quotes for a full financial overview. 22M. T. Register for your free account today at data. We also use them to share usage. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. In 2022, THTX's revenue was 80. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. 2% per year. See a list of the most recent Stock Forum posts on Stockhouse. Theratechnologies’ R&D staff is bearing the brunt of. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. Stockhouse. - Q3 2022 North American Revenue Growth of 19%. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. - October 10, 2023) - KO Gold Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. About Us | Theratechnologies Inc. 68 to a day high of $1. By continuing to use our service, you agree to our use of cookies. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. Stockhouse. Further. 9 million and US. Company Description: Theratechnologies is pepped up on peptides. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 9 million as at August 31, 2023. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. 4. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 1-514-336-7800. By continuing to use our service, you agree to our use of cookies. The Company currently commercializes two products in the field of HIV. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. The firm offers its product under the brand name of. sBLA for F8 formulation of tesamorelin submitted to FDA. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. com uses cookies on this site. View real-time stock prices and stock quotes for a full financial overview. is a speaker and consultant of Theratechnologies. Theratechnologies reduces R&D head count to compensate for sales setback. Shares of Theratechnologies are up 4. com. (TH. By continuing to use our service, you agree to our use of cookies. This news release constitutes a “designated news release” for the purposes. $30. Agreement in principle on key amendments to loan. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. Theratechnologies inc. MONTREAL, Jan. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 00 to $36. The price has fallen in 7 of the last 10 days and is down by -30. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. We also use them to share usage information with our partners. Conjugating the short peptide with various anti-cancer agents allows for. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. Once expert advice is considered, the Company. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. MONTREAL, Feb. Message Board Total Posts: 4. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 06 million, an increase of. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. Theratechnologies Inc. MONTREAL, Sept. Stockhouse. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. This news release constitutes a “designated news release” for the purposes of the Company’s. Theratechnologies inc. T. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Oct. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Cookies are used to offer you a better browsing experience and to. Trogarzo® and. 54% and a negative trailing twelve-month return on equity of. The company reported ($0. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 1-438. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. : Nasdaq Theratechnologies Inc. Stockhouse. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. 75%. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. . In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. ET. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. About TH1902. Cookies are used to offer you a better browsing experience and to analyze our traffic. If you have HIV, it's important to know the difference. Stockhouse. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Senior Director, Investor Relations. lgibson. com uses cookies on this site. By Nick Paul Taylor Jul 12, 2023 8:57am. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. 31K. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. Theratechnologies Announces 1-for-4 Reverse Stock Split. com uses cookies on this site. Get the latest Sernova Corp (SVA) real. We currently market prescription products for people with HIV in the United States. Real-time discussion about Theratechnologies Inc. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. MONTREAL, Feb. 4%. stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Website. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Stockhouse. TH | July 20, 2023. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Stockhouse. MONTREAL, Sept. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. 's motion for leave to commence. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. Biopharmaceutical company Theratechnologies Inc. The company develops treatments for lipodystrophy . ("Theratechnologies" or the "Company"). Theratechnologies Provides Details About R&D Day Webcast. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. The company was. FAQ – Émetteurs inscrits NOUVEAU. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 9 million and US$19. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. By continuing to use our service, you agree to our use of cookies. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. (TH. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. 86 million for the quarter. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. Company Type For Profit. Senior Director, Communications & Corporate Affairs. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. Gary Littlejohn. View real-time stock prices and stock quotes for a full financial overview. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Data presented at AMCP Nexus 2023. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. Montréal, Québec, Canada . The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. We also use them to share usage information with our partners. (TH. OTCQX – this is the premium tier of OTC stocks. Investor Relations. 69, 1. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. 51 to 200 Employees. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. L. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. Theratechnologies Inc. TH Stock Message Board for Investors. 81 million for the quarter. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. com uses cookies on this site. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. MONTREAL, Aug. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. About SORT1+ Technology™ and TH1902. Heures de négociation. Theratechnologies Inc. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. Investor inquiries: Elif McDonald. Theratechnologies develops and commercializes innovative therapies. MONTREAL, Feb. Senior Director, Communications & Corporate Affairs. TH | February 28, 2023. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. Theratechnologies Inc. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. 4. 11/05/2020 4:15:02 PM. Theratechnologies Inc. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. By continuing to use our service, you agree to our use of cookies. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Cookies are used to offer you a better browsing experience and to analyze our traffic. 69 to $1. By continuing to use our service, you agree to our use of cookies. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Nov. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. 89 52. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. We also use them to share usage. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. 71. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. We also use them to share usage information with our partners. com uses cookies on this site. Biopharmaceutical company Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. com uses cookies on this site. m. Cookies are used to offer you a better browsing experience and to analyze our traffic. The abstracts are now available at aacr. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. stock price gained 1. com uses cookies on this site. stock news by MarketWatch. com uses cookies on this site. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Theratechnologies Inc. -based clinical sites participating in the conduct of the Phase. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. stock price gained 6. (THTX) stock. Pour les émetteurs. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. 5000 0. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. com uses cookies on this site. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. com uses cookies on this site. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Christian Marsolais, Ph. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. com. D. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. (THTX) stock. MONTREAL, Oct. By continuing to use our service, you agree to our use of cookies. US Headquarters. Statut du système de négociation. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 8 million. View real-time stock prices and stock quotes for a full financial overview. m. We currently market. is a pharmaceutical company. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. com uses cookies on this site.